B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Neil Chatterji has maintained a 'Buy' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $28 to $18.
August 15, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OptimizeRx's price target has been lowered from $28 to $18 by B. Riley Securities, though the 'Buy' rating is maintained.
The lowering of the price target by B. Riley Securities could potentially lead to a short-term negative impact on OptimizeRx's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100